What You Should Know:
– Densitas®, a provider of artificial intelligence solutions for breast cancer screening, announced a strategic partnership with Intelerad Medical Systems®, a provider of medical imaging software and services to advance AI-driven breast cancer screening.
– This partnership strengthens clinical decision-making, increases operational efficiencies, reduces costs, and improves mammography quality and mammography facility adherence with MQSA EQUIP standards.
AI-Powered Enhancements for Breast Cancer Screenings
As part of the partnership, Densitas intelliMammo® will provide actionable information to clinical care teams, managers, and administrators when and where it is needed by leveraging the international scale of Intelerad’s IntelePACS® diagnostic imaging and PenRad® breast imaging reporting systems. This partnership will deliver a unique end-to-end solution for breast imaging facilities.
intelliMammo Background
intelliMammo® is a mammography enterprise software platform that comprises AI engines that generate breast density, mammography positioning quality, and breast cancer risk assessments that support enhanced workflows and continuous mammography quality improvement. Actionable insights from advanced analytics support better patient care, increased operational efficiencies, and strengthened compliance with FDA MQSA EQUIP and American College of Radiology (ACR) standards for mammography facilities. intelliMammo® densityAI™ is a deep learning algorithm that generates standardized and automated breast density assessments from mammograms that align with the ACR BI-RADS® breast tissue composition density scale.
“We are excited about this strategic alliance that will instantaneously expand the reach of our intelliMammo® AI platform, extending it to 2,500 healthcare organizations that form Intelerad’s install base. intelliMammo® is the nervous system of the breast imaging enterprise. Our advanced AI solutions for mammography inject intelligence and insights into the clinical, administrative, and service delivery needs of breast cancer screening providers,” said Mo Abdolell, CEO of Densitas.
